Skip to main content

Table 4 Distribution of treatments received and progression of dieses between both groups

From: The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis

Treatment C3GN
(n = 10)
C3 Controls
(n = 21)
p value
aRAS blockers (%) 70 (n = 7) 85 (n = 18) 0.3
Steroids (%) 30 (n = 3) 72 (n = 15) 0.05
bMMF (%) 20 (n = 2) 33 (n = 7) 0.4
cTac (%) 0 10 (n = 2) 1
dCP (%) 10 (n = 1) 14 (n = 3) 1
eCsA (%) 0 19 (n = 4) 0.3
fAZA (%) 0 10 (n = 2) 1
No immunosuppression (%) 40 (n = 4) 28 (n = 6) 0.7
Missing data (%) 20 (n = 2) 0 0.09
Immunosuppression (%) 40 (n = 4) 72 (n = 15) 0.4
Median Duration of immunosuppression (days) 263 (IQR 126–629) 302 (IQR 184–1496) 0.5
  1. Mann Whitney and Fishers exact test used
  2. aRAS Renin-angiotensin system blockade, bMMF Mycophenolate mofetil, cTac Tacrolimus, dCP cyclophosphamide, eCsA Ciclosporin, fAZA azathioprine